BHVN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 22:00):

Stats
Dagens volum	1.12M
Gjennomsnittsvolum	1.32M
Markedsverdi	3.25B
EPS	$0 ( 2024-03-28 )
Neste inntjeningsdato	( $-1.500 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.95
ATR14	$0.0690 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Bailey Gregory	Buy	25 503	Common Shares
2024-04-22	Bailey Gregory	Buy	48 780	Common Shares
2024-04-22	Childs John W	Buy	97 560	Common Shares
2024-04-22	Childs John W	Buy	73 170	Common Shares
2024-04-22	Childs John W	Buy	24 391	Common Shares

INSIDER POWER
96.70
Last 99 transactions
Buy: 15 309 473 \| Sell: 296 589

Volum Korrelasjon

Lang: 0.37 (neutral)

Kort: 0.88 (strong)

Signal:(63.042) Same movement expected

Biohaven Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner
THD	0.906
KB	0.888
SHG	0.882
NUVB	0.877
BKF	0.871
MX	0.866
YINN	0.866
RAYC	0.862
HBI	0.859
EDC	0.858

10 Mest negative korrelasjoner
CMO	-0.872
CSLT	-0.808

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Biohaven Pharmaceutical Korrelasjon - Valuta/Råvare

-0.23
( neutral )

-0.30
( neutral )

-0.74
( moderate negative )

-0.22
( neutral )

0.81
( strong )

0.55
( weak )

Biohaven Pharmaceutical Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-3.37M (0.00 %)
EPS:	$-5.73

FY	2023
Omsetning:	$0
Bruttogevinst:	$-3.37M (0.00 %)
EPS:	$-5.73

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.39M (0.00 %)
EPS:	$-12.75

Financial Reports:

No articles found.

Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.